Vanguard Global Advisers
IPSC icon

Vanguard Global Advisers’s Century Therapeutics IPSC Stock Holding History

Vanguard Global Advisers’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$109K Hold
44,616
– – ﹤0.01% 2735
2026
Q1 		$101K Buy
+44,616
New +$93.8K ﹤0.01% 2723

Other funds holding IPSC

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Vanguard Global Advisers's IPSC Position: Q2 2026 in Review

Vanguard Global Advisers held its Century Therapeutics (IPSC) position steady in Q2 2026 at 44,616 shares worth $109K. The position accounts for ﹤0.01% of the portfolio, ranked #2735.

Vanguard Global Advisers first reported a position in IPSC in Q1 2026 and has held it in 2 quarters since. 98 funds tracked by Wall St. Rank hold IPSC as of Q2 2026.

  • Vanguard Global Advisers held 44,616 shares of Century Therapeutics worth $109K as of Q2 2026.
  • Vanguard Global Advisers left its Century Therapeutics share count unchanged in Q2 2026.
  • Century Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2735 holding.
  • Vanguard Global Advisers first reported a position in Century Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 98 funds tracked by Wall St. Rank held Century Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.